HK Stock Market Move | JUNSHI BIO (01877) rises by over 3%, focus on AACR conference JS207 and JS212 data readout.

JUNSHI BIO (01877) rose by more than 3%, with a 2.83% increase to 28.32 Hong Kong dollars as of the time of publication, with a trading volume of 108 million Hong Kong dollars. On the news front, the global oncology conference, the American Association for Cancer Research (AACR) Annual Meeting 2026, will be held at the San Diego Convention Center in the United States from April 17 to 22. Pacific Securities pointed out that JUNSHI BIO's JS207 (PD-1/VEGF) will disclose clinical data on 1LCRC (combination chemotherapy) and 1LHCC (combination CTLA4 monoclonal antibody) at the 2026 AACR conference, with the possibility of entering key registration clinical trials within the year; JS212 (EGFR/HER3ADC) will disclose early-stage data at AACR and plans to initiate key registration clinical trials by the end of the year.